Peripheral Vascular Diseases
📧 Sign up to get email alerts when something new happens for Peripheral Vascular Diseases.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS withdrawal · 2025-04-10Clinical Trial Update: Mind Body Program for Vascular Disease [NA]
The Mind Body Program for Vascular Disease trial (NCT05757752) has been withdrawn.
-
EMA withdrawal · 2021-01-25EMA Withdrawn: Clopidogrel ratiopharm GmbH (clopidogrel) — Archie Samiel s.r.o.
EMA withdrew clopidogrel from Archie Samiel s.r.o.'s product line, with therapeutic areas including peripheral vascular diseases, acute coro…
-
EMA withdrawal · 2018-01-04EMA Withdrawn: Clopidogrel Acino (clopidogrel) — Acino AG
Clopidogrel Acino has been withdrawn from the European market.
-
EMA withdrawal · 2017-10-24EMA Withdrawn: Clopidogrel Teva Pharma (previously Clopidogrel HCS) (clopidogrel (as hydrochloride)) — Teva B.V.
EMA withdrew Clopidogrel Teva Pharma (clopidogrel hydrochloride) from the market.
-
EMA withdrawal · 2015-07-10EMA Withdrawn: Clopidogrel DURA (clopidogrel (as hydrochloride)) — Mylan dura GmbH
The EMA has withdrawn Clopidogrel DURA (clopidogrel hydrochloride) from the market for peripheral vascular diseases, stroke, and myocardial …
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
EMA withdrawal · 2015-02-03EMA Withdrawn: Clopidogrel Teva Pharma B.V. (clopidogrel (as hydrobromide)) — Teva Pharma B.V.
The EMA withdrew clopidogrel Teva Pharma B.V. (clopidogrel as hydrobromide) from marketing.
-
EMA withdrawal · 2014-09-08EMA Withdrawn: Clopidogrel Qualimed (clopidogrel (as hydrochloride)) — Qualimed
EMA withdrew Clopidogrel Qualimed (clopidogrel hydrochloride) from the market.
-
EMA withdrawal · 2014-05-12EMA Lapsed: Clopidogrel Teva Generics B.V. (clopidogrel (as hydrochloride)) — Teva Pharma B.V.
EMA has lapsed the marketing authorization for Clopidogrel Teva Generics B.V. (clopidogrel as hydrochloride).
-
EMA withdrawal · 2013-12-12EMA Withdrawn: Clopidogrel ratiopharm (clopidogrel) — Archie Samuel s.r.o.
Withdrawn clopidogrel product (Clopidogrel ratiopharm) listed by EMA; therapeutic areas include peripheral vascular diseases, stroke, and my…
-
EMA withdrawal · 2013-04-22EMA Withdrawn: Possia (ticagrelor) — AstraZeneca AB
Possia (ticagrelor) has been withdrawn from market authorization by AstraZeneca AB.
-
EMA withdrawal · 2012-07-26EMA Withdrawn: Clopidogrel Hexal (clopidogrel) — Acino Pharma GmbH
Clopidogrel Hexal (clopidogrel) has been withdrawn from the market by Acino Pharma GmbH.
-
EMA withdrawal · 2012-07-26EMA Withdrawn: Clopidogrel Acino Pharma GmbH (clopidogrel) — Acino Pharma GmbH
Clopidogrel product from Acino Pharma GmbH has been withdrawn from the market.
-
EMA withdrawal · 2012-07-26EMA Withdrawn: Clopidogrel Acino Pharma (clopidogrel) — Acino Pharma GmbH
The EMA withdrew Clopidogrel Acino Pharma (clopidogrel) from use; linked to peripheral vascular diseases, stroke, and myocardial infarction …
-
EMA withdrawal · 2011-10-26EMA Withdrawn: Clopidogrel Sandoz (clopidogrel) — Acino Pharma GmbH
The EMA indicates withdrawal of Clopidogrel Sandoz (clopidogrel) by Acino Pharma GmbH.
-
EMA withdrawal · 2010-01-26EMA Withdrawn: Clopidogrel BMS (clopidogrel (as hydrogen sulfate)) — Bristol-Myers Squibb Pharma EEIG
The EMA information indicates that the clopidogrel BMS product (clopidogrel as hydrogen sulfate) has been withdrawn from the market.
-
EMA withdrawal · 2008-05-27EMA Application withdrawn: DuoCover (clopidogrel;acetylsalicylic acid) — Bristol Myers Squibb Pharma EEIG
EMA withdrew the application for DuoCover (clopidogrel and acetylsalicylic acid) from Bristol Myers Squibb Pharma EEIG.
-
EMA withdrawal · 2008-05-27EMA Application withdrawn: DuoPlavin (clopidogrel;acetylsalicylic acid) — Sanofi Pharma Bristol-Myers Squibb
EMA withdrew the application for DuoPlavin (clopidogrel and acetylsalicylic acid) by Sanofi Pharma Bristol-Myers Squibb.